Chiusura precedente | 1.705,00 |
Aperto | 0,00 |
Denaro | 0,00 x 0 |
Lettera | 0,00 x 0 |
Min-Max giorno | 0,00 - 0,00 |
Intervallo di 52 settimane | |
Volume | |
Media Volume | 8.263.272 |
Capitalizzazione | 70,489B |
Beta (5 anni mensile) | 0,27 |
Rapporto PE (ttm) | 15,86 |
EPS (ttm) | 1,09 |
Prossima data utili | 31 lug 2024 |
Rendimento e dividendo (futuro) | 0,60 (3,52%) |
Data ex dividendo | 16 mag 2024 |
Stima target 1A | N/D |
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
STAMFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that data from two collaborator-sponsored clinical studies evaluating nirogacestat, an investigational oral gamma secretase inhibitor, in combination with B-cell maturation agent (BCMA) therapies in patients with relapsed or refractory multiple my
SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment from GSK of $90 million upon deal close with future performance-based milestone payments of up to $503 million and tiered royalties.SCYNEXIS ended Q1 with cash, cash equivalents and short-term investments of $54.8 million, and upon receipt of the upfront payment from GSK will have a projecte